Navigation Links
Allergic-like reactions to iodinated contrast material treated safely with commonly used medications
Date:8/1/2008

Patients who have had acute allergic-like reactions to nonionic iodinated contrast material rarely develop any serious long-term problems and can be treated safely with commonly used medications according to a recent study conducted by researchers at the University of Michigan Hospitals in Ann Arbor.

"While adverse reactions to iodinated contrast media are rare, they are encountered regularly by all physicians who administer contrast material to patients and some of these reactions will require treatment," said Richard Cohan, MD, lead author of the study. "We reviewed our experience to determine how often we encountered these reactions in our practice and how often the reactions required treatment. We also wanted to know what happened to those patients who required treatment, particularly when they had reactions that were moderate or severe," said Dr. Cohan.

The study consisted of 84,928 IV injections of nonionic iodinated contrast media in adults. In this group, there were 545 (0.6%) patients who had allergic-like reactions, with 221 receiving treatment. The most commonly administered medications were diphenhydramine to 145 (27%) reacting patients, corticosteroids to 17 patients, albuterol to 16 patients, ephinephine to 15 patients, and nitroglycerin to eight patients. According to the study, 99% of the allergic-like reactions resolved completely within 24 hours. This included all 418 patients who had mild reactions, all 116 patients who had moderate reactions, and nine of the 11 patients who had severe reactions.

"Commonly used medications can be administered safely; however, treatment errors are not uncommon and in a few instances can lead to patient morbidity," said Dr. Cohan. "In our study, we found a number of instances in which non-recommended treatment was provided. These cases included the administration of oxygen by nasal cannula (rather than mask) and at lower than recommended doses, over-utilization of diphenhydramine (including to a few patients who were hypotensive), and the administration of higher than recommended doses of epinephrine, as well as occasional confusion about which concentrations of epinephrine should be injected in which manner (subcutaneously or intravenously). In our study, the most striking example of patient morbidity from non-recommended treatment occurred in the two patients who received doses of 1 mg of epinephrine in the absence of cardiopulmonary arrest, who both had cardiac complications. Fortunately, these complications were mild and transient and caused no serious morbidity," he said.

"We hope that after reading our study, radiologists, nurses, and technologists will agree that they must review the algorithms for treating contrast reactions on a regular basis (particularly issues related to diphenhydramine, oxygen, and epinephrine administration)," said Dr. Cohan. "In fact, we would suggest that such a review should probably occur at least twice a year. However, it is also consoling to know that even when patients have moderate or severe contrast reactions, the vast majority recover promptly and without any long term complications," he said.


'/>"/>

Contact: Necoya Tyson
necoya@arrs.org
703-858-4304
American Roentgen Ray Society
Source:Eurekalert

Related medicine news :

1. Allergic-like reactions occur in premedicated patients
2. London School of Hygiene to play key role in global collaboration on adverse drug reactions
3. DOCTORS OPPOSE MARYLAND VACCINE ROUNDUP: Expect Dangerous Reactions When Children Are Treated Like Cattle
4. MDs reactions to pharma marketing influenced by brand, side effects: Management Insights
5. Allergic reactions to gadolinium-based contrast agents are rare, study finds
6. U of I scientists aim to overcome allergic reactions to soy
7. PA Department of Health Warns Consumers About Adverse Reactions From Dietary Supplements
8. Consumer Alert: Black Henna Tattoos Can Cause Serious Skin Reactions
9. Bayer HealthCare Pharmaceuticals and MedAssets Supply Chain Systems Sign a Three-Year Agreement for Magnevist(R) Magnetic Resonance Contrast Media
10. Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
11. DyCE(TM) (Dynamic Contrast Enhancement) Technology Now Part of CRis Analysis Software Suite for the Popular Maestro(TM) in vivo Molecular Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with ... to schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing ... directory will bring more Six Month Smiles patients to their providers.” , Each month, ...
(Date:7/26/2017)... ... July 26, 2017 , ... Isodiol ... global cannabis innovator, specializing in the development of pharmaceutical and consumer products, announces ... 2017 to June 30, 2017. Iso International LLC recorded unaudited fiscal Q1 profits ...
(Date:7/26/2017)... ... 26, 2017 , ... BioPlus Specialty Pharmacy (BioPlus), ... of the HCV Treatment Path app (version 4.4.0) to keep health care providers ... All of the latest HCV medications are included in this app, including Vosevi™ ...
(Date:7/25/2017)... , ... July 25, 2017 , ... Summers in Palm ... the air conditioner — think homemade gourmet ice cream, sparkling pools, and mile-high fun. ... shop featuring fun mugs, journals, and other must-have knick knacks. Ice cream and sorbet ...
(Date:7/25/2017)... ... July 25, 2017 , ... SureVest Insurance ... services to communities across North Carolina, is launching a charity event in conjunction ... support for the ongoing fight against bladder cancer. , The Bladder Cancer Advocacy ...
Breaking Medicine News(10 mins):
(Date:7/24/2017)... IBM (NYSE: IBM ) has been recognized as a ... for the fourth year in a row. 1 ... the Leaders quadrant have the highest scores for their Ability ... Leaders quadrant has the market share, credibility, and marketing and ... These vendors demonstrate a clear understanding of market needs; they ...
(Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) announced today that ... before the market opens on Thursday, July 27, 2017. ... host a teleconference on Thursday, July 27, 2017, at ... dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast ...
(Date:7/20/2017)... , July 20, 2017  Prime Therapeutics LLC (Prime) released ... , M.D., following today,s Institute for Clinical and Economic Review,s ... on the effectiveness and value of abuse-deterrent formulations (ADF) of ... policy roundtable at the meeting. ... material cost benefit to the use of abuse-deterrent formulations (ADF) ...
Breaking Medicine Technology: